| 1 |
Editorial The trialist, meta-analyst, and journal editor: lessons from ADAPT. 2007
Martin BK, Breitner JC, Evans D, Lyketsos CG, Meinert CL. · Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md, USA. · Am J Med. · Pubmed #17349436 No free full text.
This publication has no abstract.
|
| 2 |
Article Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. free! 2008
Anonymous00079, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. · No affiliation provided · Arch Neurol. · Pubmed #18474729 links to free full text
Abstract: BACKGROUND: Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs. OBJECTIVE: To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults. DESIGN: Randomized, double-masked chemoprevention trial. SETTING: Six US memory clinics. PARTICIPANTS: Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment. INTERVENTIONS: Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively. MAIN OUTCOME MEASURES: Seven tests of cognitive function and a global summary score measured annually. RESULTS: Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over time for both treatment groups compared with placebo (- 0.33 points for celecoxib [P = .04] and - 0.36 points for naproxen [P = .02]). Restriction of analyses to measures collected from persons without dementia attenuated the treatment group differences. Analyses limited to measures obtained while participants were being issued study drugs produced results similar to the intention-to-treat analyses. CONCLUSIONS: Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen.
|
| 3 |
Article Women and alzheimer disease. 1999
Evans D, Ganguli M, Harris T, Kawas C, Larson EB. · Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA. · Alzheimer Dis Assoc Disord. · Pubmed #10609666 No free full text.
This publication has no abstract.
|
| 4 |
Minor ADAPT trial data. free! 2007
Breitner J, Evans D, Lyketsos C, Martin B, Meinert C. · No affiliation provided · Am J Med. · Pubmed #17349430 links to free full text
This publication has no abstract.
|
|
|